Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe.
Frentz D, Van de Vijver DA, Abecasis AB, Albert J, Hamouda O, Jørgensen LB, Kücherer C, Struck D, Schmit JC, Vercauteren J, Åsjö B, Balotta C, Beshkov D, Camacho RJ, Clotet B, Coughlan S, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Stanekova D, Stanojevic M, Van Wijngaerden E, Wensing AM, Boucher CA; SPREAD Programme. Frentz D, et al. Among authors: van wijngaerden e, van de vijver da. BMC Infect Dis. 2014 Jul 21;14:407. doi: 10.1186/1471-2334-14-407. BMC Infect Dis. 2014. PMID: 25047543 Free PMC article. Clinical Trial.
A combination of poor adherence and a low baseline susceptibility score is highly predictive for HAART failure.
Van Vaerenbergh K, De Geest S, Derdelinckx I, Bobbaers H, Carbonez A, Deschamps A, De Graeve V, De Saar V, Ceunen H, De Smet K, Maes B, Peetermans W, Schrooten Y, Desmyter J, De Clercq E, Van Ranst M, Van Wijngaerden E, Vandamme AM. Van Vaerenbergh K, et al. Among authors: van wijngaerden e, van ranst m. Antivir Chem Chemother. 2002 Jul;13(4):231-40. doi: 10.1177/095632020201300404. Antivir Chem Chemother. 2002. PMID: 12495211 Free article.
Performance of the VERSANT HIV-1 resistance assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes.
Derdelinckx I, Van Laethem K, Maes B, Schrooten Y, De Schouwer K, De Wit S, Fransen K, García Ribas S, Moutschen M, Vaira D, Zissis G, Van Ranst M, Van Wijngaerden E, Vandamme AM. Derdelinckx I, et al. Among authors: van laethem k, van wijngaerden e, van ranst m. FEMS Immunol Med Microbiol. 2003 Nov 28;39(2):119-24. doi: 10.1016/S0928-8244(03)00240-2. FEMS Immunol Med Microbiol. 2003. PMID: 14625094 Free article.
Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001.
Snoeck J, Van Laethem K, Hermans P, Van Wijngaerden E, Derdelinckx I, Schrooten Y, van de Vijver DA, De Wit S, Clumeck N, Vandamme AM. Snoeck J, et al. Among authors: van laethem k, van wijngaerden e, van de vijver da. J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):279-85. doi: 10.1097/00126334-200403010-00009. J Acquir Immune Defic Syndr. 2004. PMID: 15076243
Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment response.
Derdelinckx I, Van Laethem K, Maes B, Schrooten Y, De Wit S, Florence E, Fransen K, Ribas SG, Marissens D, Moutschen M, Vaira D, Zissis G, Van Ranst M, Van Wijngaerden E, Vandamme AM. Derdelinckx I, et al. Among authors: van laethem k, van wijngaerden e, van ranst m. J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1664-6. doi: 10.1097/00126334-200412150-00022. J Acquir Immune Defic Syndr. 2004. PMID: 15577426 Free article. Clinical Trial. No abstract available.
A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypes.
Van Laethem K, Schrooten Y, Dedecker S, Van Heeswijck L, Deforche K, Van Wijngaerden E, Van Ranst M, Vandamme AM. Van Laethem K, et al. Among authors: van wijngaerden e, van heeswijck l, van ranst m. J Virol Methods. 2006 Mar;132(1-2):181-6. doi: 10.1016/j.jviromet.2005.10.008. Epub 2005 Nov 4. J Virol Methods. 2006. PMID: 16271771
No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs.
Van Laethem K, De Munter P, Schrooten Y, Verbesselt R, Van Ranst M, Van Wijngaerden E, Vandamme AM. Van Laethem K, et al. Among authors: van wijngaerden e, van ranst m. J Clin Virol. 2007 May;39(1):43-7. doi: 10.1016/j.jcv.2007.02.003. Epub 2007 Mar 21. J Clin Virol. 2007. PMID: 17369083
157 results